ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant Staph aureus(MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas aeruginosa. Source
No articles found.
Checkpoint Therapeutics, Inc. (âCheckpointâ) is a clinical-stage, immuno-oncol...
Checkpoint Therapeutics, Inc. (âCheckpointâ...
Headquartered in Franklin, Tennessee, Acadia Healthcare was established in January...
Headquartered in Franklin, Tennessee, Acadia He...
aTyrâs mission is to translate newly discovered biological pathways to develop i...
aTyrâs mission is to translate newly discover...
Syneos HealthÂŽ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solut...
Syneos HealthÂŽ (Nasdaq:SYNH) is the only fully...
Infinity Pharmaceuticals, Inc. is an innovative biopharmaceutical company dedicate...
Infinity Pharmaceuticals, Inc. is an innovative...
Nektar Therapeutics is a research-based development stage biopharmaceutical compan...
Nektar Therapeutics is a research-based develop...
At Aethlon Medical, we are a leading developer of immunotherapeutic technologies t...
At Aethlon Medical, we are a leading developer ...
Join the National Investor Network and get the latest information with your interests in mind.